date,title,source
Oct-22-18,"VistaGen Therapeutics to Present at Credit Suisse 27th Annual Healthcare Conference on Wednesday, November 14, 2018",GlobeNewswire
Oct-25-18,"VistaGen Therapeutics Acquires Worldwide Rights to Develop and Commercialize PH10, a First-in-Class Intranasally Administered Neuroactive Steroid with Rapid-onset Antidepressant Effects for Major Depressive Disorder Demonstrated in Phase 2a Study",GlobeNewswire
Oct-29-18,VistaGen Therapeutics Reports Fiscal 2019 Second Quarter Financial Results,GlobeNewswire
Oct-29-18,"Health Care Digest: A small biotech goes head first, Gilead's lower tax rate and more",American City Business Journals
Nov-12-18,VistaGen Therapeutics Receives Notices of Allowance in Australia and Japan for AV-101 Patents Covering Treatment of Depression,GlobeNewswire
Nov-15-18,"Consolidated Research: 2018 Summary Expectations for Tapestry, Mallinckrodt public limited company, Moxian, Applied Genetic Technologies, VistaGen Therapeutics, and Oasis Midstream Partners LP  Fundamental Analysis, Key Performance Indications",GlobeNewswire
Nov-29-18,VistaGen Therapeutics Receives Hong Kong Patent for Methods of Production for AV-101,GlobeNewswire
Dec-21-18,"Do Institutions Own VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Shares?",Simply Wall St.
Dec-27-18,VistaGen Therapeutics to Present at 11th Annual Biotech Showcase,GlobeNewswire
Jan-15-19,"VistaGen Therapeutics Appoints Pharmaceutical Industry Veteran, Ann Cunningham, to its Board of Directors",GlobeNewswire
Jan-31-19,AV-101 Stimulates the Formation of New Brain Cells in Nonclinical Studies,GlobeNewswire
Feb-05-19,"VistaGen Therapeutics to Present at the 21st Annual BIO CEO & Investor Conference on February 11, 2019",GlobeNewswire
Feb-12-19,VistaGen Therapeutics Reports Fiscal 2019 Third Quarter Financial Results,GlobeNewswire
Feb-13-19,VistaGen Therapeutics Receives Notice of Allowance for U.S. Patent for Treatment of Depression with PH10,GlobeNewswire
Feb-13-19,"The Daily Biotech Pulse: Exelixis Q4 Results, FDA Panel Greenlights J&J's Depression Drug, MacroGenics Prices Offering",Benzinga
Feb-14-19,"FDA Panel Nod for J&J's Esketamine Is Good News for Allergan, Vistagen",GuruFocus.com
Feb-19-19,VistaGen Therapeutics Receives AV-101 Japanese Patent for Treatment of Depression and Hyperalgesia,GlobeNewswire
Feb-25-19,VistaGen Therapeutics Announces Proposed Public Offering of Common Stock,GlobeNewswire
Feb-26-19,VistaGen Therapeutics Announces Pricing of Underwritten Public Offering of Common Stock,GlobeNewswire
Feb-27-19,Four Tech Stocks Looking To Test February Highs,ACCESSWIRE
Mar-07-19,"VistaGen Therapeutics to Present at the Cowen and Company 39th Annual Health Care Conference on March 13, 2019",ACCESSWIRE
Mar-13-19,VistaGen Therapeutics Receives Notice of Allowance for Additional U.S. Patent Regarding Methods of Production for AV-101,ACCESSWIRE
Mar-14-19,"VistaGen Therapeutics to Present at the Oppenheimer 29th Annual Healthcare Conference on March 19, 2019",ACCESSWIRE
Mar-28-19,VistaGen Therapeutics Receives Australian Patent for Treatment of Depression with AV-101,ACCESSWIRE
Apr-01-19,"Positive Pilot Phase 3 Data Position VistaGen's PH94B Neuroactive Nasal Spray for Pivotal Phase 3 Development as a Novel, As-Needed Treatment for Social Anxiety Disorder",ACCESSWIRE
Apr-03-19,"VistaGen Therapeutics to Participate in the William Blair 3rd Annual Late-Stage Therapeutics Conference on April 4, 2019",ACCESSWIRE
May-02-19,Vistagen Shares Fall Under $1 After Depression Drug Flunks Midstage Trial,Benzinga
May-02-19,VistaGen Reports Top Line Results from NIMH's Exploratory Study of AV-101 Monotherapy for Treatment-Resistant Depression,ACCESSWIRE
May-07-19,"VistaGen Therapeutics to Present at ChinaBio(R) Partnering Forum in Shanghai, China",ACCESSWIRE
May-30-19,"VistaGen Announces Positive Preclinical Data Supporting AV-101's Potential for Treating Neuropathic Pain Comparable to Pregabalin (Lyrica(R)), without its Side Effects",ACCESSWIRE
